Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in South Korea / NCT06260865
Active, not recruiting Not applicable

A Confirmatory Trial of Multidisciplinary Digital Therapeutics for Patellofemoral Pain Syndrome

NCT06260865 · tracked via the Priya Life Science South Korea tracker
Sponsor
Phase
Not applicable
Started
2024-04-26
Last updated
2025-01-23

Condition(s) studied

Patellofemoral Pain Syndrome

Investigational drug(s) / intervention(s)

MORA CureTreatment as Usual

MORA Cure: MORA Cure (ETH-01K), developed by EverEx, Inc., is a digital therapeutics (S/W medical device) designed to provide multidisciplinary rehabilitation treatment, a combination of graded exercise therapy and cognitive behavioural therapy for patients with patellofemoral pain syndrome.

Treatment as Usual: In the control group, education is delivered and self-exercise is recommended.

Study summary

This randomized controlled confirmatory study will be evaluating an mobile application, MORA Cure (ETH-01K), owned by EverEx, Inc., to examine safety and effectiveness in individuals with patellofemoral pain syndrome.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Patients with peripatellar or posterior patellar pain in one or more knee joints for 3 months or longer 2. Patients with peripatellar or posterior patellar pain provoked by squatting 3. Patients who have pain provoked by 2 or more following activities: prolonged sitting, cycling, running, going up or down stairs, kneeling, compression of the patella, palpation of the patellar facets 4. Patients who signed a written informed consent form Exclusion Criteria: 1. Patients with osteoarthritis which scored 3 or higher grade of the Kellgren-Lawrence scale 2. Patients diagnosed with a fracture or dislocation around the knee within the last 3 months 3. Patients who had knee surgery within the last 3 months 4. Patients diagnosed with patellar tendinitis based on imaging within 3 months 5. Patients taking narcotic pain medications for pain control 6. Patients taking or planning to take any medication that is a contraindication within the next 16 weeks at the time of screening 7. Patients who are pregnant 8. Patients currently participating in another clinical trial or have participated in another clinical trial within the past 3 months at the time of screening 9. Patients deemed unsuitable for this study by the investigator

Primary outcome measure(s)

Trial sites (10)

FacilityCityRegionStatus
Myongji Hospital Goyang-si Gyeonggi-do
Hanyang University Guri Hospital Guri-si Gyeonggi-do
Seoul National University Bundang Hospital Gyeonggi-do Gyeonggi-do
CHA Bundang Medical Center Seongnam-si Gyeonggi-do
Inha University Hospital Junggu Incheon
Chung-Ang University Hospital Dongjak Seoul
Seoul Metropolitan Government-Seoul National University Boramae Medical Center Dongjak Seoul
Kyung Hee University Hospital at Gangdong Gangdong Seoul
The Catholic University of Korea Seoul St. Mary's Hospital Seocho Seoul
Asan Medical Center Seoul Seoul

More EverEx Inc. trials in South Korea

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06260865 on ClinicalTrials.gov ↗ ← All trials in South Korea